FDA-approved Product
Therapy Areas
Sanofi’s rare blood disorder franchise is focused on hemophilia A and B with or without inhibitors, immunothrombocytopenia and acquired thrombotic thrombocytopenic purpura (aTTP).
Educational Resources
Hemophilia
Trends in the Hemophilia Treatment Landscape
An overview of the history of hemophilia care, currently approved therapies, the comprehensive patient care model and introduction to products currently in the hemophilia therapy pipeline.
Associated Clinical Guidelines and Recommendations
NHF MASAC | National Hemophilia Foundation Medical and Scientific Advisory Council | 2022
WFH | World Federation of Hemophilia | 2020
ISTH | International Society of Thrombosis and Haemostasis |2024
Immunothrombocytopenia
ITP Disease Overview and Therapeutic Landscape
An overview of the clinical presentation and disease burden with ITP, currently approved therapies, comprehensive review of the current ASH 2019 guidelines and pipeline therapies.
ASH 2019 Guidelines for ITP
Acquired Thrombotic Thrombocytopenic Purpura
Sanofi does not review or control the content of non-Sanofi websites.
Engage with Sanofi Payer Medical
Explore Other Therapy Areas
Immunology and Inflammation Resources
Neurology Resources
Oncology Resources
Member Engagement and Population Health Resources
